Frankfurt - Delayed Quote EUR

Chimerix, Inc. (CXF.F)

7.48

+0.02

+(0.27%)

At close: April 17 at 9:55:01 PM GMT+2

Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025?

We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s ‘Closing […]

Insider Monkey 18 days ago

CMRX
Exploring US High Growth Tech Stocks In March 2025

In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability in response to evolving market dynamics.

Simply Wall St. 19 days ago

ENFN

CMRX

APLS
Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025

We recently published a list of the 11 Best Performing Stocks So Far In 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against the other best performing stocks so far in 2025. On March 21, Jason Pride, Chief of Investment Strategy at Glenmede, and Stephen DeNichilo, […]

Insider Monkey 24 days ago

CMRX
Chimerix: Q4 Earnings Snapshot

The Durham, North Carolina-based company said it had a loss of 25 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share.

Associated Press Finance 29 days ago

CMRX
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing dea

GlobeNewswire 29 days ago

CMRX
LTRN: M&A Illuminates GBM Value

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) continues to enroll its HARMONIC trial for LP-300 at sites around the globe with the most recent focus on Taiwan and Japan, where the prevalence of never-smoker non-small cell lung cancer (NSCLC) is from two to three times higher than in the United States. Lantern’s RADR (Response Algorithm

Zacks Small Cap Research last month

LTRN

CMRX
Why Chimerix, Inc. (CMRX) Soared Last Week

We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week’s Top Performers. In this article, we are going to take a look at where Chimerix, Inc. (NASDAQ:CMRX) stands against the other stocks. Micro- and small-cap companies dominated the stock market last week, clocking in impressive gains on the back of a flurry […]

Insider Monkey last month

CMRX

JAZZ
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment in accordance with Nasdaq Listing rule 563

GlobeNewswire last month

CMRX
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.

Zacks last month

MRNA

CMRX

JAZZ
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More

CMRX and JAZZ are in the spotlight this week following an acquisition agreement.

Zacks last month

CMRX

MRNA

JAZZ
Update: Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating

(Updated to include analyst commentary) Truist Securities raised Jazz Pharmaceuticals price targ

PREMIUM
MT Newswires last month

JAZZ

CMRX

TFC
Chimerix downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ). The total consideration of approximately $935M reflects about a 72% premium to the closing price on March 4, the analyst noted. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on CMRX: Chimerix downgraded to Neutral from Ou

TipRanks last month

CMRX
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.

Zacks last month

JAZZ

CMRX
Jazz Pharmaceuticals bids for Chimerix in $935m deal

The acquisition will give Jazz access to Chimerix’s lead investigational candidate dordaviprone.

Pharmaceutical Technology last month

CMRX

JAZZ

GLDAF
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix"), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million. The transaction has been approved by both companies and is expected to close in the second quarter of 2025.

PR Newswire last month

CMRX

JAZZ
Jazz expands in oncology with $935M deal for Chimerix

Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.

BioPharma Dive last month

CMRX

JAZZ
Exploring Three High Growth Tech Stocks in the United States

In the last week, the United States market has been flat, yet it has shown a robust 21% increase over the past year, with earnings expected to grow by 14% annually in the coming years. In this context of overall market growth and stability, identifying high growth tech stocks involves looking for companies with strong innovation potential and solid financial health that can capitalize on these favorable conditions.

Simply Wall St. last month

CMRX

RARE

MVIS
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

Potential First Approval for Patients with Recurrent H3 K27M-mutant Diffuse Glioma PDUFA Target Action Date of August 18, 2025 No Advisory Committee Meeting Currently Planned to Discuss Application DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted its

GlobeNewswire last month

CMRX
Metalpha Technology Holding And 2 Other US Penny Stocks To Monitor

As the S&P 500 flirts with record highs and major indexes post weekly gains, investors are keenly observing market dynamics to identify potential opportunities. Penny stocks, despite their somewhat outdated moniker, continue to attract attention for their potential value and growth prospects. Typically representing smaller or newer companies, these stocks can offer unique opportunities for growth at lower price points when backed by strong financials and sound fundamentals.

Simply Wall St. 2 months ago

CMRX

MATH

SANA
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know

Chimerix stock surges 324% in three months following NDA submission for high-grade glioma drug, dordaviprone, for accelerated approval in the United States.

Zacks 2 months ago

CMRX

Performance Overview

Return	CXF.F	S&P 500 (^GSPC)
YTD	+117.44%	-10.18%
1-Year	+790.48%	+5.19%
3-Year	+70.23%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Chimerix, Inc. (CXF.F)

Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025?

Exploring US High Growth Tech Stocks In March 2025

Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025

Chimerix: Q4 Earnings Snapshot

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

LTRN: M&A Illuminates GBM Value

Why Chimerix, Inc. (CMRX) Soared Last Week

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More

Update: Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating

Chimerix downgraded to Neutral from Buy at H.C. Wainwright

Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio

Jazz Pharmaceuticals bids for Chimerix in $935m deal

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

Jazz expands in oncology with $935M deal for Chimerix

Exploring Three High Growth Tech Stocks in the United States

Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma

Metalpha Technology Holding And 2 Other US Penny Stocks To Monitor

CMRX Stock Skyrockets in 3 Months: Here's What You Should Know

Performance Overview